心房颤动筛查:美国预防服务工作组推荐声明
美国预防服务工作组(USPSTF)基于系统综述更新2018年推荐,评估≥50岁无症状且无房颤诊断或症状、无短暂性脑缺血发作或卒中史成人筛查房颤的获益与危害。工作组认为证据不足,无法确定筛查的获益与危害平衡,给出I级声明。
要点
- USPSTF认为当前证据不足以评估≥50岁无症状成人筛查房颤的获益与危害平衡(I声明)。
- 房颤患病率随年龄增长,55岁以下成人低于0.2%,85岁及以上约10%,男性高于女性。
- 约20%的房颤相关卒中患者在卒中时或卒中后不久才首次诊断房颤。
核心结论
- USPSTF认为当前证据不足以评估筛查房颤的获益与危害平衡(I声明)。
研究设计与样本
- 美国预防服务工作组(USPSTF)委托系统综述,评估老年人筛查房颤的获益与危害、筛查试验准确性、筛查试验较常规护理检测未诊断房颤的效果以及筛查检出房颤抗凝治疗的获益与危害。
主要发现
- 房颤患病率随年龄增长,55岁以下成人低于0.2%,85岁及以上约10%,男性高于女性。
- 房颤是缺血性卒中的主要危险因素,约20%的房颤相关卒中患者在卒中时或卒中后不久才首次诊断房颤。
- USPSTF认为证据不足,无法确定无症状成人筛查房颤的获益与危害平衡。
关键数值与推荐
- USPSTF对≥50岁、无房颤诊断或症状且无短暂性脑缺血发作或卒中史的成人筛查房颤给出I声明。
临床怎么用
- 原文未据此给出推荐。
局限性
- USPSTF认为证据不足,无法确定筛查房颤的获益与危害平衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Atrial fibrillation (AF) is the most common cardiac arrhythmia. The prevalence of AF increases with age, from less than 0.2% in adults younger than 55 years to about 10% in those 85 years or older, with a higher prevalence in men than in women. It is uncertain whether the prevalence of AF differs by race and ethnicity. Atrial fibrillation is a major risk factor for ischemic stroke and is associated with a substantial increase in the risk of stroke. Approximately 20% of patients who have a stroke associated with AF are first diagnosed with AF at the time of the stroke or shortly thereafter. OBJECTIVE: To update its 2018 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review on the benefits and harms of screening for AF in older adults, the accuracy of screening tests, the effectiveness of screening tests to detect previously undiagnosed AF compared with usual care, and the benefits and harms of anticoagulant therapy for the treatment of screen-detected AF in older adults. POPULATION: Adults 50 years or older without a diagnosis or symptoms of AF and without a history of transient ischemic attack or stroke. EVIDENCE ASSESSMENT: The USPSTF concludes that evidence is lacking, and the balance of benefits and harms of screening for AF in asymptomatic adults cannot be determined. RECOMMENDATION: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for AF. (I statement).
引用
- Davidson KW, Barry MJ, Mangione CM, et al. Screening for Atrial Fibrillation: US Preventive Services Task Force Recommendation Statement. JAMA. 2022. PMID: 35076659. doi:10.1001/jama.2021.23732
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。